[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[Merus N.V. Common Shares](/topic/$mrus)

### Sentiment: XX%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$mrus/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$mrus/time-series/sentiment.tsv)  
**Current Value**: XX%  
**Daily Average**: XX%  
**1 Week**: XXX% +14%  
**1 Month**: XX% +6%  
**6 Months**: XX% -XX%  
**1 Year**: XX% +6%  
**1-Year High**: XXX% on 2025-01-26  
**1-Year Low**: X% on 2024-11-17  

**Most Supportive Themes**
- **Positive Clinical Trial Data:** (60%) Positive clinical trial results of Merus's drug, petosemtamab, particularly its high response and survival rates in head and neck cancer patients.
- **Analyst Price Target Increases:** (20%) Several social media posts highlight analysts raising price targets for MRUS based on the promising clinical trial data.
- **Acquisition by Genmab:** (15%) Genmab is acquiring Merus for $XX per share in cash, a deal valued at $X billion.
  
**Most Critical Themes**
- **Trial Data Comparison Concerns:** (1%)  Some users are expressing concerns over comparing trial results with different patient populations and treatment contexts.
  
Network engagement breakdown:  
| Network | Positive | %   | Neutral | %   | Negative | %  |
| ------- | -------- | -   | ------- | -   | -------- | -  |
| X       | XXXXX    | XX% | XXXXX   | XX% | XX       | X% |
| YouTube | X        | X%  | X       | X%  | X        | X% |
| Reddit  | X        | X%  | X       | X%  | X        | X% |
|         |          |     |         |     |          |    |
| Total   | XXXXX    | XX% | XXXXX   | XX% | XX       | X% |